The influence of gender on survival and tumor recurrence following adjuvant therapy of completely resected stages II and IIIa non-small cell lung cancer

Lung Cancer

Volumn 37, Issue 3, 2002, Pages 303-309

  Keller, S M ^a   Vangel, M G ^b   Adak, S ^b   Wagner, H ^c   Schiller, J H ^d   Herskovic, A ^e   Komaki, R ^f   Perry, M C ^g   Marks, R S ^h   Livingston, R B ⁱ   Johnson, D H ^j  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e Oakwood Hospital   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g UNIVERSITY OF MISSOURI   (United States)

^h MAYO CLINIC   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j VANDERBILT UNIVERSITY   (United States)

more..

Author keywords

Adjuvant therapy; Gender; Non small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; PROTEIN P53;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; CISPLATIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; SEX FACTORS; SURVIVAL;

EID: 0036754178     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00103-4     Document Type: Conference Paper

References (23)

1. Williams D.E., Pairolero P.C., Davis C.S., et al. Survival of patients surgically treated for stage I lung cancer. J. Thorac. Cardiovasc. Surg. 82:1981;70-76.
2. Mitsudomi T., Tateishi M., Oka T., et al. Longer survival after resection of non-small cell lung cancer in Japanese women. Ann. Thorac. Surg. 48:1989;639-642.
3. Ouellette D., Desbiens G., Emond C., et al. Lung cancer in women compared with men: stage, treatment, and survival. Ann. Thorac. Surg. 66:1998;1140-1144.
4. Ferguson M.K., Wang J., Hoffman P.C., et al. Sex-associated differences in survival of patients undergoing resection for lung cancer. Ann. Thorac. Surg. 69:2000;245-250.
5. de Perrot M., Licker M., Bouchardy C., et al. A. Sex differences in presentation, management, and prognosis of patients with non-small cell lung carcinoma. J. Thorac. Cardiovasc. Surg. 119:2000;21-26.
6. Minami H., Yoshimura M., Miyamoto Y., et al. Lung cancer in women. Chest. 118:2000;1603-1609.
7. Keller S.M., Adak S., Wagner H., et al. A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II and IIIa non-small cell lung cancer. N. Engl. J. Med. 343:2000;1217-1222.
8. Schiller J.H., Adak S., Feins R.H., et al. Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group randomized trial of postoperative adjuvant therapy. J. Clin. Oncol. 19:2001;448-457.
9. Mountain C.F. A new international staging system for lung cancer. Chest. 89:(Suppl.):1986;225S-232S.
10. Tisi G.M., Friedman P.J., Peters R.M., et al. Clinical staging of primary lung cancer. Am. Rev. Respir. Dis. 127:1983;659-670.
11. Mehta C.R., Patel N.R. A network algorithm for performing Fisher's exact test in rxc contingency tables. J. Am. Stat. Assoc. 78:1983;427-434.
12. Kaplan E.L., Meier P. Nonparametric estimation of incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50:1966;163-170.
14. Cox D.R. Regression models and life tables (with discussion). J. Roy. Stat. Soc. Ser. B. 34:1972;187-220.
15. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics, 2001. CA Cancer J. Clin. 51:2001;15-36.
16. Zang E.A., Wynder E.L. Differences in lung cancer risk between men and women: examination of the evidence. J. Natl. Cancer Inst. 88:1996;183-192.
17. Risch H.A., Howe G.R., Jain M., et al. Are female smokers at higher risk for lung cancer than male smokers? A case control analysis by histologic type. Am. J. Epidemiol. 138:1993;281-293.
18. Dresler C.M., Fratelli C., Babb J., et al. Gender differences in genetic susceptibility for lung cancer. Lung Cancer. 30:2000;153-160.
19. Tang D.L., Rundle A., Warburton D., et al. Associations between both genetic and environmental biomarkers and lung cancer: evidence of a greater risk of lung cancer in women smokers. Carcinogenesis. 19:1998;1949-1953.
20. Shriver S.P., Bourdeau H.A., Gubish C.T., et al. Sex-specific expression of gastrin-releasing peptide receptor: relationship to smoking history and risk of lung cancer. J. Natl. Cancer Inst. 92:2000;24-33.
21. Schreiber G., Fong K.M., Peterson B., et al. Smoking gender, and survival association with allele loss for LOH11B lung cancer region on chromosome 11. Cancer Epidemiol. Biomarkers Prev. 6:1997;315-319.
22. D'Amico T.A., Aloia T.A., Moore M., et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann. Thorac. Surg. 69:2000;882-886.
23. McDuffie H.H., Klaassen D.J., Dosman J.A. Female-male differences with primary lung cancer. Cancer. 59:1987;1825-1830.